Asuragen’s microRNA-based test, miRInform Pancreas, has demonstrated improvements in the diagnosis of pancreatic ductal adenocarcinoma.
The data from the multicentre study involving 186 subjects showed that the miRNA-based molecular test will improve the diagnostic accuracy of fine-needle aspiration cytology on indeterminate and suspicious specimens.
Go deeper with GlobalData
miRInform Pancreas, along with standard fine-needle aspiration cytology, allows pancreatic ductal adenocarcinoma to be diagnosed with 92.5% accuracy, as compared to 80.2% for fine-needle aspiration cytology alone.
Brigham and Women’s Hospital Dr Darwin Conwell said that the microRNA-based molecular test helps to identify false negative cytology.
The molecular test will be available in the company’s CLIA Laboratory from 1 December 2011.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
